Galapagos NV

Activities: Research & Development Pharmaceutical

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to...
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    How CDMOs can set a new gold standard when it comes to going green Sustainability is more than a feel-good initiative or a choice; it’s a strategic imperative. Not missing a beat, pharma companies have been making a concerted effort towards...
  3. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human...
  4. Mastering modified-release performance: excipient considerations Imagine a world where enhanced therapeutic efficacy, improved patient compliance and reduced adverse effects are tangible outcomes — even for drugs with short pharmacokinetic...
  5. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

Drug Delivery

Galapagos and NovAliX enter integrated drug discovery collaboration

The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and immunology
Research & Development

Galapagos expands fibrosis portfolio

Fibrosis small molecule programme has been announced as the focus of a partnership between Galapagos and Evotec
Research & Development

Pharnext announces R&D agreement with Galapagos

The main goal of this agreement is to generate an additional pipeline of novel synergistic drug combinations in a broad set of indications
Research & Development

Galapagos ends inflammation partnership with Janssen

Long-running alliance started in 2007
Research & Development

AbbVie and Galapagos to co-develop cystic fibrosis therapies

Firms aim to start Phase 1 trials at end of 2014
Research & Development

Galapagos appoints CEO of Service Division

David Smith returns to the Belgian firm in new role
Research & Development

Galapagos receives €2.5m grant for IBD research

IWT-funded project aims to identify new compounds for future treatment of IBD
Subscribe now